APOGEN BIOTECHNOLOGIES
ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
APOGEN BIOTECHNOLOGIES
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.apogenbiotech.com
Total Employee:
1+
Status:
Active
Contact:
(206)957-7300
Email Addresses:
[email protected]
Total Funding:
11 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF WordPress Apache Wordpress Plugins Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS
Similar Organizations
Dauntless Pharmaceuticals
Dauntless Pharmaceuticals is a biotechnology company that focuses on the development of drugs.
Divide and Conquer
Divide & Conquer is a biotechnology company focused on discovery and development of a new class of oncology therapeutics
Current Advisors List
Current Employees Featured
Founder
Investors List
M Ventures
M Ventures investment in Series A - ApoGen Biotechnologies
Alexandria Venture
Alexandria Venture investment in Series A - ApoGen Biotechnologies
ARCH Venture Partners
ARCH Venture Partners investment in Series A - ApoGen Biotechnologies
Johnson & Johnson Innovation
Johnson & Johnson Innovation investment in Series A - ApoGen Biotechnologies
WuXi AppTec
WuXi AppTec investment in Series A - ApoGen Biotechnologies
Watson Fund
Watson Fund investment in Series A - ApoGen Biotechnologies
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Series A - ApoGen Biotechnologies
Eli Lilly
Eli Lilly investment in Series A - ApoGen Biotechnologies
Accelerator Corp.
Accelerator Corp. investment in Series A - ApoGen Biotechnologies
Washington Research Foundation
Washington Research Foundation investment in Series A - ApoGen Biotechnologies
Official Site Inspections
http://www.apogenbiotech.com
- Host name: 172.67.148.11
- IP address: 172.67.148.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ApoGen Biotechnologies" on Search Engine
ApoGen Biotechnologies, Inc. - Development of a New Class of …
ApoGen Biotechnologies Expands Series A Financing to $11 Million and Enhances Leadership Team. Accelerator Corporation Announces $7M Series A Investment in ApoGen Biotechnologies to Develop a New Class of Drugs Targeting Resistance to Cancer Therapy. ApoGen Biotechnologies Raises $7 Million Series A.See details»
ApoGen Biotechnologies - Crunchbase Company Profile & Funding
ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics. Seattle, Washington, United States. 1-10. Series A. Private. www.apogenbiotech.com/ 68,760. Highlights. Total Funding Amount. Unlock for free. Contacts 3. Employee Profiles 2. Investors 11. Similar Companies 5. Company Insights.See details»
ApoGen Biotechnologies Company Profile 2024: Valuation, …
Description. Developer of advanced therapies intended to break drug resistance in cancer. The company develops therapies that target key drivers of ongoing deoxyribonucleic acid mutation and tumor evolution, thereby enabling physicians to …See details»
ApoGen Biotechnologies, Inc. | LinkedIn
ApoGen Biotechnologies, Inc. | 487 followers on LinkedIn. As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy,...See details»
Startup Profile: ApoGen Biotechnologies | RIO
Dec 4, 2014 ApoGen Biotechnologies Inc. is developing new drug therapies that will make cancer treatments more effective. The company is based on scientific discoveries by the University of Minnesota’s Reuben Harris, Ph.D., professor of biochemistry, molecular biology and biophysics, and Daniel Harki, Ph.D., assistant professor of medicinal chemistry.See details»
ApoGen Biotechnologies Company Profile - Craft
$11 M. Company Summary. Overview. ApoGen Biotechnologies is developing novel oncology therapeutics targeting the key drivers of mutation and cancer genomic evolution to overcome drug resistance. Our lead target is APOBEC3B (A3B), a DNA cytosine deaminase and an important endogenous source of DNA mutation in cancer.See details»
New Class of Drugs Targeting Resistance to Cancer Therapy
About ApoGen Biotechnologies ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics targeting drivers of cancer genomic mutation. ApoGen is building upon technologies developed at the University of Minnesota to develop drugs that block a key pathway that causes drug …See details»
ApoGen Biotechnologies Expands Series A Financing to $11 …
Seattle, WA – August 23, 2018 – ApoGen Biotechnologies, Inc., a company developing a new class of drugs that target the underlying mechanisms that lead to the development of drug resistance by cancer cells, today announced the expansion of its Series A financing to a total of $11 million.See details»
Accelerator’s ApoGen nets new biochem leaders, plus an additional …
By Conor Hale Aug 23, 2018 6:00am. Drug Resistance personnel announcements startups venture capital (VC) ApoGen Biotechnologies has brought on Chrysalis Therapeutics founder Stephen Gwaltney,...See details»
ApoGen Biotechnologies Expands Series A Financing to $11 …
Aug 23, 2018 SEATTLE-- ( BUSINESS WIRE )--ApoGen Biotechnologies, Inc., a company developing a new class of drugs that target the underlying mechanisms that lead to the development of drug resistance by...See details»
ApoGen Biotechnologies expands series A financing to $11m
By PBR Staff Writer. Recommended companies. ApoGen Biotechnologies, a biotechnology firm engaged in the development of a new class of therapeutics targeting drivers of cancer genomic mutations, has expanded its series A financing to a total of $11m.See details»
Apogen Biotechnologies | VentureRadar
Founded in 2015. Private Company. "ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics targeting drivers of cancer genomic mutation. ApoGen is building upon technologies developed at the University of Minnesota to develop drugs that block a key pathway that causes drug …See details»
ApoGen Biotechnologies | CipherBio
ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics. Stage: Public. Total Funds Raised: $0.00. Funding Products Partners People News Network. See all funding and science results with CipherBio PRO. Find Prospects. Identify leads, gain more opportunities, close more deals. $1.665 TrillionSee details»
ApoGen Biotechnologies raises $11M via series A financing
Aug 24, 2018 ApoGen Biotechnologies Inc. raised a total of $11 million in its series A financing. The Seattle-based biotechnology said Merck Ventures BV, the venture capital …See details»
ApoGen Biotechnologies - Funding, Financials, Valuation
ApoGen Biotechnologies is funded by 11 investors. M Ventures and Alexandria are the most recent investors. ApoGen Biotechnologies has a post-money valuation in the range of $50M to $100M as of Aug 23, 2018, according to PrivCo.See details»
ApoGen Biotechnologies - Updates, News, Events, Signals
ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics.See details»
Research programme: cancer therapeutics - ApoGen Biotechnologies …
ApoGen Biotechnologies is developing drugs targeting the mechanisms that cause genomic mutations to interrupt the development of drug resistance via cancer Research programme: cancer therapeutics - ApoGen Biotechnologies - AdisInsightSee details»
ApoGen Biotechnologies, Inc. - Pharmaceuticals - Apollo.io
ApoGen Biotechnologies, Inc. Pharmaceuticals. Private company. Founded in 2014. +1 206-957-7300. Seattle, Washington. apogenbiotech.com. /apogen-biotechnologies-inc- Employees. Technologies. Alumni. ApoGen Biotechnologies, Inc. information.See details»
ApoGen Biotechnologies – Accelerator
ApoGen Biotechnologies, Inc. focused on the development of a new class of therapeutics targeting drivers of cancer genomic mutations. ApoGen built upon technologies developed at the University of Minnesota to develop drugs …See details»
ApoGen Biotechnologies - Contacts, Employees, Board …
ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics.See details»